Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01582191
Other study ID # 2011-0953
Secondary ID NCI-2012-0078209
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date May 14, 2012
Est. completion date May 31, 2026

Study information

Verified date January 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) or highest dose level, and the dose-limiting toxicity (DLT) of vandetanib (a multi-kinase inhibitor of epidermal growth factor receptor [EGFR], vascular endothelial growth factor receptor [VEGFR] and ret proto-oncogene [RET] inhibitor) when used in combination with everolimus (a mammalian target of rapamycin [mTOR] inhibitor) in advanced cancer. II. Preliminary descriptive assessment of the anti-tumor efficacy of the combination. III. Preliminary optional assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response. OUTLINE: This is a dose-escalation study. Patients receive vandetanib orally (PO) once daily (QD) and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment patients are followed up between 14-28 days at the discretion of the treating physician.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 153
Est. completion date May 31, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months. - Patients must be at least 3 weeks beyond their previous cytotoxic chemotherapy. - Patient must be at least 5 half-lives or 3 weeks, whichever is shorter, from their previous targeted or biologic therapy; In addition, patients must be at least 3 weeks beyond the last session of radiation therapy. Local palliative radiation therapy that is not delivered to all target lesions is allowed immediately before or during treatment. - ECOG performance status should be less or equal to 3 - Patients must have organ and marrow function defined as: Absolute neutrophil count more or equal to 750/mL; platelets more or equal to 50,000/mL; creatinine less or equal to 3x ULN; total bilirubin less than or equal to 3.0. - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence). Exclusion Criteria: - Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support. - Pregnant or lactating women. - History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation. - History of hypersensitivity to sirolimus, temsirolimus, everolimus. - History of hypersensitivity to any component of the formulation. - Patients unwilling or unable to sign informed consent document. - Presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia. - History (within the last 3 months) or presence of stroke/cerebrovascular accident. - Congenital long QT syndrome. - QTcF interval greater than 500 ms that is not correctable to less than 500ms such as with cessation of a causative medication, etc. - History of myocardial infarction within 6 months with a residual arrhythmia that in the opinion of the Investigator, increases the risk of ventricular arrhythmia. - Presence of a symptomatic bradyarrhthmia or uncompensated heart failure.

Study Design


Intervention

Drug:
Everolimus
Given PO
Other:
Laboratory Biomarker Analysis
Optional correlative studies
Pharmacological Study
Optional correlative studies
Drug:
Vandetanib
Given PO

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose Will be defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33%. Toxicity will be reported by type, frequency, and severity. Worst toxicity grades per patient will be tabulated for selected adverse events and laboratory measurements. 28 days
Primary Anti-tumor efficacy of the combination in terms of response rate The response rate will be estimated by dose level and tumor type, along with the exact 95% confidence interval. Efficacy will be evaluated by using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria described in the supplement for response. Patients with lymphoma will be measured per the World Health Organization (WHO) criteria. Up to 14 years
Primary Maximum observed serum concentration (Cmax) Will be estimated using standard non-compartmental methods Days 1 and 21 of course 1 and day 1 of course 3
Primary Pharmacodynamic (PD) parameters PD biomarker concentration will be summarized by time points. The relationship between drug concentrations and PD effects will be explored graphically. Based on review of these graphs, analyses to describe the relationship may also be performed. Up to 14 years
Primary Observed trough serum concentration (Cmin) Will be estimated using standard non-compartmental methods Days 1 and 21 of course 1 and day 1 of course 3
Primary Area under the serum concentration-time curve (AUC) Will be estimated using standard non-compartmental methods Days 1 and 21 of course 1 and day 1 of course 3
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Recruiting NCT05048160 - A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm Phase 1/Phase 2
Active, not recruiting NCT03287492 - RCT of QPS vs General Information Sheet N/A
Recruiting NCT01549067 - The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey N/A
Recruiting NCT04119037 - Cordotomy in Reducing Pain in Patients With Advanced Cancer N/A
Recruiting NCT04067336 - First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT00244972 - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Phase 1
Recruiting NCT06297642 - TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. Phase 1
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT04186884 - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Completed NCT02583269 - Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Phase 1
Withdrawn NCT03868423 - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Phase 2
Terminated NCT02940223 - Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Active, not recruiting NCT03021486 - Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer Phase 2/Phase 3
Recruiting NCT03203525 - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Phase 1
Completed NCT01624766 - Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Phase 1
Not yet recruiting NCT06394713 - A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors Phase 1/Phase 2

External Links